The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease

Digestive Diseases and Sciences

Volumn 52, Issue 9, 2007, Pages 2359-2367

  Akyüz, Filiz ^a,b   Demir, Kadir ^a   Özdil, Sadakat ^a   Aksoy, Nevzat ^a   Poturoǧlu, Şule ^a   Ibrişim, Duygu ^a   Kaymakoǧlu, Sabahattin ^a   Beşişik, Fatih ^a   Boztaş, Güngör ^a   Çakaloǧlu, Yilmaz ^a   Mungan, Zeynel ^a   Çevikbaş, Uǧur ^a   Ökten, Atilla ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Nonalcoholic fatty liver disease; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; METFORMIN; ROSIGLITAZONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIET; DRUG EFFICACY; EXERCISE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SAFETY; STEATOSIS; TREATMENT RESPONSE;

ADULT; BIOPSY; DIET, FAT-RESTRICTED; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERCISE THERAPY; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; TRANSAMINASES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 34547569865     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9145-x     Document Type: Article

References (26)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434-438
2. Day CP, James OFW (1998) Hepatic steatosis: innocent bystander or guilty party? Hepatology 27:1463-1466
3. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ (1999) Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29:664-669
4. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M (2002) Expanding the natural history of non-alcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134-140
5. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419
6. Drenick EJ, Simmons F, Murphy JF (1970) Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small bowel bypass. N Engl J Med 282:829-834
7. Andersen T, Gluud C, Franzmann MB, Christoffersen P (1991) Hepatic effects of dietary weight loss in morbidly obese patients. J Hepatol 12:224-229
8. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K (1997) Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27:103-107
9. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB (1996) Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic-induced steatohepatitis: A pilot study. Hepatology 23:1464-1467
10. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenky-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174
11. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N (2001) Metformin in nonalcoholic steatohepatitis. Lancet 358:893-894
12. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K (2004) Metformin in the treatment of patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 19:537-544
13. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL (2001) A pilot study of thiazolidinedione, troglitazone, in non-alcoholic steatohepatitis. Am J Gastroenterol 96:519-525
14. Mayerson, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802
15. Tetri-Neuschwander BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR (2003) Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 38:1008-1017
16. Day CP (2003) Management future targets in NAFLD. In ''Non Alcoholic Fatty Liver Disease'' President's premeeting syllabus. 38th annual meeting of the European Association for the study of the liver; Tozun N, Avsar E (eds). Istanbul, A & G Agency, pp 58-65.
17. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH (2004) A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188-196
18. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J (2002) NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373-379
19. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467-2474
20. Harrison SA, Torgerson S, Hayashi PH, Ward J, Schenker S (2003) Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98:2485-2490
21. KadayIfcI A (2003) Nonalcoholic steatoepatitis: Role of leptin in pathogenesis and benefits of metformin in treatment. Am J Gastronterol 98:2330
22. Lin HZ, Yang SQ (2003) Current biochemical studies of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach. Am J Gastroenterol 98:495-499
23. Fan JG, Zhong L, Xu ZJ, Tia LY, Ding XD, Li MS, Wang GL (2003) Effects of low calori diet on steatohepatitis in rats with obesity and hyperlipidemia. World J Gastroenterol 9:2045-2049
24. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA (1994) Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107:1103-1109
25. Angulo P, Keach JC, Batts KP, Lindor KD (1999) Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 30:1356-1362
26. Ipekci SH, Basaranoglu M, Sonsuz A (2003) The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 18:1220-1221